Biocurious: The cannabis stocks that stand out in a field of weeds
Regulators have lax telehealth prescribers in their sights
Althea Group has sold its medical pot arm in favour of THC-infused beverages
Having sprouted in a field of hope and hype eleven years ago, the ASX medicinal cannabis sector has wilted in the face of unrealistic expectations and misguided strategies.
Demand isn't the problem: patients have embraced medical weed zealously since it was legalised a decade ago.
Globally, most western countries have sanctioned both medical usage and many have condoned recreational indulgence (including most US states).
Because there's only two approved cannabis treatments, local dispensing is largely carried out via an authorised prescriber scheme.
In the six months to December 2024, these docs wrote 377,840 prescriptions. Of these, 230,091 were for products with a THC content of more than 98%.
Patients aren't mucking around.
What's not to like?
The answer is rampant oversupply of the green stuff coupled with the rise of telehealth clinics, some of which are being criticised for alleged 'tick and flick' dispensing practices.
Echoing Australian Medical Association concerns, Little Green Pharma (ASX:LGP) CEO Paul Long refers to 'poor actors' in the local market.
'Reports constantly refer to a handful of doctors, often junior doctors that are either being coerced, or paid exorbitant money to write a huge volume of THC scripts,' he says.
'I agree it is an issue and calling it out for the long-term growth of our industry is important."
He adds hundreds of thousands have tried medical cannabis when nothing has worked, with great success.
Reflecting the 'commoditised' market, Althea Group (ASX:AGH) in May sold its local medical cannabis business, Tasmanian Botanics Pty Ltd for a knock-down $1 million.
'The market has become irrational,' says Althea CEO Joshua Fegan.
'It's very saturated, with product from places like Canada, South Africa and Colombia'.
He says most of the consumption is by way of dried flower, which implies folk might be smoking the devil's lettuce for jollies rather than using it medicinally.
We'll delve further into Althea's new direction below.
The dope on how to get it right
While most suppliers have withered, a handful prosper via differentiated strategies and perhaps a bit of luck. They are producing meaningful revenues and – in some cases - profits.
The Perth-based Little Green Pharma derives 80% of its revenue from the local market, but its greater fortunes align to the rapidly evolving European market.
Germany is in the throes of partial legalisation.
In France, the company supplies a pilot program that's a precursor to legalisation.
Little Green's owns a production facility in Denmark – Europe's biggest – purchased from Canada's Canopy Growth for a knock-down $20 million three years ago.
Two hours from the German border, the facility provides a streamlined route to the biggest Continental markets.
'It's very unlikely a site like this will be built again in the foreseeable future,' Little Green CEO Paul Long says.
Meanwhile, the company's Busselton facility becomes a 'craft' producer of a small amount of slowly cured, hand trimmed, genetically superior stuff.
Naturally, this attracts a better margin.
In the year to March 2025 Little Green grew its revenue by 43%, to a record $36.8 million 'against a backdrop of significant regulatory change and intense competition'.
European revenues doubled.
Adjusted for non-cash items, Little Green managed underlying earnings of $2.9 million compared with a previous $1.6 million loss.
From gummies to suppositories
Bioxyne (ASX:BXN) has a modest $64 million market cap, but that's big enough to confer 'sector leader' status.
Bioxyne's engine room is Breathe Life Sciences (BLS), acquired via scrip in 2023.
BLS makes and distributes medical cannabis and other consumer health products, either under its own brands or third-party labels.
(locally, Bioxyne is also the only licensed maker of MDMA and psilocybin for authorised prescribers and pyschedelic clinical trials).
In 2019 the company launched in the UK and Japan via its well-known Dr Watson brand, covering everything from gummies, to vapes to suppositories.
BLS too has entered the German market with a deal to supply a minimum 1.6 tonnes of cannabis flower and finished product to two clients.
The company expects the agreement will reap a minimum of $5.6 million of revenue in the 2025-26 year.
Ja, das ist gut!
Bioxyne CEO Sam Watson expects German demand to rapidly overtake the $1 billion a year Australian market.
On June 12 the company upgraded full-revenue expectations from $25 million to $28 million, a lofty step up from the previous year's $9.65 million.
The Ebay of medicinal dope
Formerly known as Cronos Australia, Vitura Health (ASX:VIT) doesn't produce any of its own material, but operates a marketplace that sells hundreds of flowers and oils from third party suppliers.
Vitura also has expanded into prescription nicotine vapes.
The company has built a network of physical and online prescribers, mainly via acquisition.
Vitura owns the Canview marketplace, Doctors on Demand telehealth business, CDA Clinics (medical cannabis telehealth) and the clinic chain Candor Medical.
In May, Vitura's 50% joint venture Flora acquired the digital platform Heyday Medical, 'one of Australia's most respected medicinal cannabis clinics'.
Established in 2020, the chain claims to have serviced more than more than 5000 patients.
Last November Flora acquired the Releaf Group, which operates telehealth and physical clinics.
In a March quarter update, Vitura said full-year revenue was unlikely to meet the targeted 10% improvement. But the June quarter implies a yearly run rate of $138 million, up 11%.
Management also expects a 20% improvement on last year's normalised underlying earnings of $8.4 million.
Putting the pep into soft drinks
Coming back to Althea, the company's new schtick is entering the North American market for THC-infused beverages.
(THC is the psychoactive component of cannabis).
Yep, these bevvies are legal in Canada and the US and are sold in bottle shops alongside alcohol.
Althea's foray is by way of its subsidiary Peak.
Althea's Fegan says when Peak started producing in 2021, only 4% of cannabis consumers had tried these drinks. Now, the number is more like one-quarter of them.
He says the drinks have a similar effect to a similar sized serve of alcohol, but without the hangover.
'It ticks a lot of boxes as a good consumer product,' he says.
Peak's competitive edge is its technique to produce the THC emulsion, without the 'planty' taste of dope.
Peak's offerings include seltzers, sodas and mocktails – but it's not yet putting the 'pep' into Pepsi.
Peak Canada has just launched its own brand Snap Back, a heady mix of THC and rosin (pine resin).
By December Althea expects to have four or five US production sites, as close to distributors as possible.
'These big alcohol companies are looking closely at this space and our job is to develop drinks for those type of companies and produce them at scale," Fegan says.
In the December half, Althea derived $8.2 million of revenue in Canada and the company expects this to grow during the summer months.
Given the sale of its Australian business, Althea in May withdrew its full-year guidance of revenue between $26-33 million and underlying earnings of $800,000 to $1.1 million.
Althea lost $2.6 million in the March quarter. But Fegan says the company should be cash flow positive without the drag of the divested Australian business.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
18 minutes ago
- ABC News
Victorian government housing agency hires home-buyer as part of public housing demolition plans
The Victorian government's housing agency is hiring an internal home-buyer as it works to find new homes for residents displaced by its controversial plan to redevelop Melbourne's public housing towers. The successful candidate will work with Homes Victoria to identify properties that are suitable for leasing or purchase, "including bulk and off-the-plan purchases". They will also have a thorough understanding of the property market and transaction process, according to a job advertisement that closes tomorrow. Homes Victoria regularly purchases and leases properties to add to the state's social housing stock, but the job ad's mention of a "high priority Tower Relocations program" suggests acquisitions could scale up as the 44 towers are progressively retired over the next 25 years. While the move will likely help residents remain close to their existing communities, the government's critics say it could add more pressure to the strained property market. "Our concern is the government obviously has absolutely no plan for how they are going to house 10,000 people that they are relocating in the middle of a housing crisis," the Victorian Greens' housing spokesperson, Gabrielle de Vietri, said. "The government has said that it's simply too expensive for them to refurbish these public housing towers. "Yet what they are engaging in is an incredibly expensive and inefficient process of buying up and head-leasing private homes to move public housing residents into." The government has been under fire over the effect its plan to progressively redevelop the ageing towers, which generally house hundreds of people, will have on housing demand across the city. It is unclear how many private market homes could be required over the life of the plan, with many tenants likely to be moved into existing social housing properties. A Homes Victoria spokesperson declined to say how many private market homes would be required across the first three towers to be retired — in North Melbourne and Flemington — but the government has previously revealed four dwellings were leased and 16 dwellings purchased in surrounding suburbs in the first half of the year. It is understood the homes were acquired at market value. The Real Estate Institute of Victoria also said it was aware of a government initiative to purchase private dwellings for social housing, but its members had not reported any significant activity in that area. "Increasing supply through new builds is the most effective way to address affordability and availability over the long term," a spokesperson said. "However, we acknowledge that in some circumstances, the time frames associated with new developments may not meet urgent demand, and the use of existing stock may be a necessary interim measure." Meanwhile, the Victorian Greens say they were recently contacted by a constituent claiming a real estate agency working on behalf of the government had approached multiple owners in their inner-west Melbourne apartment block about potential sales. The movement comes as Melbourne's overburdened property market suffers from a citywide vacancy rate of 1.4 per cent, a near-record low according to property research body Cotality. Head of research Tim Lawless said additional demand against this backdrop of low supply would generally place upward pressure on rents and property prices in the inner-city suburbs where the towers were located. "I suppose from a positive perspective, it's good to see the state government looking after those tenants in government-owned properties and looking to relocate them," he said. "I think the challenge is actually going to be finding enough housing to ensure those people have a quality lifestyle and a reasonable level of comfort." The tower refurbishment plan is the focus of a current parliamentary inquiry that has heard evidence from distressed residents, legal centres and housing groups, as well as a resident-led class action that was dismissed but is currently being appealed. However, the government argues the ageing towers have reached the end of their useful life and do not meet modern standards of design, comfort and energy efficiency. It has promised to increase social housing by 10 per cent at each site when the estates are rebuilt, with a mix of social and private market housing. More than 55,500 households were waiting to enter public housing in March this year, while a further 10,500 existing tenants had applied for transfers.
News.com.au
2 hours ago
- News.com.au
The Geelong suburbs where home prices soared since Covid
Time is on the side of people who bought homes in Geelong in the first year of the Covid pandemic, new data reveals. New PropTrack research reveals people who bought homes in the 12 months to July 2020 are sitting pretty on potential five-year value gains of between 10 and 100 per cent. Only one Geelong suburb shows a price fall over that time, a 3.3 per cent decline for Geelong West units. The growth figures underline how dramatic the restrictions on the movement of people in Melbourne were on regional property prices during the pandemic, as thousands sought to leave the lockdown capital. Mid-century home designed by AFL great up for sale Dan Andrews' ring of steel locked in the unprecedented boom in home prices as waves of Melbourne people – many buying sight-unseen – accelerated demand for property. It wasn't to last though, with Geelong now coming out of a two-year downturn as the market absorbed the abnormal growth. The data reveals Rippleside as the standout suburb, with a 104 per cent median price gain over five years (worth $850,000) skewed by the waterfront Balmoral Quay development. A renovation boom made its mark at inner-west Manifold Heights, where the median house price has jumped nearly 60 per cent to $1.175m. But next-ring suburbs stood up best during the downturn. Whittington, St Albans Park, Bell Post Hill, Herne Hill and Corio houses banked median price growth between 30 and 40 per cent over five years, with inner-city South Geelong and outer suburban Lovely Banks and Marshall rounding out the city's 10 best-performing suburbs. Geelong buyers advocate Tony Slack said the strength of the growth over five years demonstrated the owning property for value gain was still a long-term proposition. 'You always should be looking at least five to seven years because of that cycle. That's just natural growth – plateau – growth – plateau. You need time in the market,' he said. Mr Slack said the pandemic boom was unique as it was driven predominantly by owner occupiers, with the negative result for Geelong West units put down to an oversupply and fewer investment buyers. Gartland Geelong agent Will Ainsworth said new development and renovations contributed significantly to the growth, especially in smaller suburbs such as Rippleside and Manifold Heights, but rising prices for inner suburbs also pushed demand further from the CBD. 'Eight to 10 years ago it would have been the suburbs closer to the CBD than those (that had the best growth),' he said. 'You've got East Geelong or Newcomb, and now you've got Whittington and St Albans Park. 'It's that next or third suburb from the CBD that became the affordable one, because that second one had taken off and become a bit less affordable,' he said. 'There's equity in two ways – improving the value in a renovation or waiting for the market to increase, or doing both. 'One of them is probably going to work, two of them are going to work better.' Geelong's best growth in five years: houses Suburb Median price 5 year change Rippleside $1,665,000 104.3% Manifold Heights $1,175,000 59.3% Whittington $540,000 40.3% Lovely Banks $805,000 40.0% St Albans Park $600,000 36.2% Bell Post Hill $655,000 35.1% Corio $490,000 34.2% Herne Hill $700,000 30.8% South Geelong $890,000 29.4% Marshall $630,000 28.8% Mr Ainsworth said buyers had become more sensible again, but there were still tricky conversations with vendors who bought at the height of the boom. 'If they bought for $1m, now it might be worth $950,000. The owners might want $1.05m to get their money back. You've got a $100,000 or 10 per cent differential that you can't bring that together – that's too big a price gap.' Hayeswinckle, East Geelong director Tiffany Simpson said returning confidence and interstate investors were improving values in areas like St Albans Park, where bigger properties offer better bang for buck. 'In almost the first six months of 2025 in St Albans Park we are up 10 per cent up on where we were last year – that's due to investors coming back in to the market,' she said. 'A lot of first-time buyers are able to stretch past $600,000, given a couple of interest rate cuts. 'The confidence has definitely returned and they feel more relaxed to able be able to fully use their borrowing potential.' Geelong's best growth in five years: units Suburb Median price 5 year change Newtown $603,000 36.4% Norlane $392,500 32.2% Bell Park $524,000 29.4% Newcomb $480,000 28.0% Corio $385,000 24.2% Whittington $375,000 22.5% Belmont $530,000 22.4% Herne Hill $355,000 22.1% Highton $502,000 21.0% Grovedale $500,000 20.1% McGrath, Geelong agent Jasmin Jurkovic said values in suburbs such as Bell Post Hill had responded as neighbouring areas heated up. 'The demographics are changing – it was a very ageing population with 80-plus year old migrants that came here 55 years ago and the built their dream home,' Ms Jurkovic said. 'The younger generation has gravitated here and appreciated the value they've got for families with land size, affordability for a good, solid brick home and all the conveniences.' Corio is the most-popular suburb in the top 10, where 291 houses sold in 12 months. The median house price has jumped from $365,000 in 2020 to $490,000. 'I became all about the bigger blocks and affordability and people were landbanking and going, 'well, it's an hour to Melbourne, first-time buyers will gravitate here if we build units',' she said. 'There's a lot of construction and building taking place and the yield was good because when you were buying something for $350,000, and the rent was about $300 to $280.'
ABC News
2 hours ago
- ABC News
The unexpected realities of receiving a cancer diagnosis when young
It wasn't until Ashlynn Heaton was about to be wheeled into theatre to have an ovarian cyst removed that doctors told her scans revealed it was probably cancer, and she'd need her right ovary and fallopian tube taken out. Aged just 26 at the time, she had already delayed the surgery by six weeks to complete a work placement and it was an abrupt interruption to a life busy with work, university and her first boyfriend. "I didn't know that cancer in young people really existed," she said. As a young woman, she was concerned about surgical scars and how to preserve her chances of having children in the future. She was also put into medical menopause and was left to deal with the symptoms. Within weeks, she broke up with her partner as the prospect of dealing with fertility questions proved too overwhelming. "The reality was that I couldn't handle having to go through this health challenge plus the relationship," she said. Determined to finish her degree, Ashlynn was soon juggling the physical demands of intense daily chemotherapy and trying to finish university assignments in hospital. "Just even standing was really hard," she said. "If I sometimes couldn't pack my bag, my mum or my sister had to pack it for me and then I'd get in the car and drive myself to chemo." She's one of an emerging group of young people receiving a cancer diagnosis. For this generation, there are limited supports. Dr Peter Diamond, Chair of Cancer Council's Supportive Care Committee, said younger patients typically accessed information online and the Cancer Council were seeing an increase in the number of clicks on information relating to cancers for younger people. "The big thing that we hear about, if you are diagnosed and have young children, is how do you talk to young children and teenagers about cancer," he said. He said younger patients were often not set up financially and had little superannuation to draw on if they were in difficulty. "People end up financially struggling quite a lot," he said. Assistance to cover dealing with treatment side effects such as fertility issues or sexual function also varied state by state. "They also have a lot longer to live with those side effects than people who would probably be diagnosed later in life," Dr Diamond said. He said there were lots of supports available but the problem was having good navigation and coordination to ensure people got help from the start and not when they reached crisis point. "What we find is that people are reluctant to call because they think that there are people out there who are way worse than what they are," he said. Treatment left Ashlynn isolated as she couldn't see friends while her immune system was suppressed. And, some of her social network didn't have the life experience to know how to properly support her. Reflecting on it now, Ashlynn said while there were many children's cancer charities and support groups, there were few options for young women. There was also limited publicly funded psychological help, especially to help navigate the anxiety around regular scans and concerns over her fertility. "Finding that new normal is a real challenge," she said. Unable to work, the medical bills started to add up and without large savings, she struggled financially. "It just it took a toll on me. Can you afford your medication? Can you afford getting fuel?" At a practical level, Ashlynn said what would have helped was transport to chemo appointments, with hospital parking costs alone adding up to about $500 during her three-month treatment. For Andrew Saliba, a bowel cancer diagnosis not only brought the perils of chemotherapy and radiation treatment, but he had to navigate its side effects while juggling two small children. "I had a port-a-cath installed — they put it under your skin just above your chest. So having that and then having the kids wanting to give you a cuddle and they climb on you — it's very painful," he said. "We were always trying to remind them to be careful of Daddy — so they kind of knew Daddy's sick in his tummy but they didn't know the extent of it." During his chemotherapy treatment and with a suppressed immune system, Andrew had to stay at his in-law's house when his family caught COVID. On another occasion, he ended up in emergency with a fever. Andrew said with each treatment his mental health declined and his relationship was put under stress. "There were lots of times I said I'm not doing any more treatment because it's too hard," he said. "I was very moody some days, so that obviously put a bit of a strain on the relationship but at the end of the day I think it has definitely brought us closer. "My wife was amazing through it. She picked up the slack." The couple were still paying off their house and as Andrew's treatments ramped up, he had to give up his job as an electrician, placing the family in financial difficulty. He said if it were not for employer-supplied income protection insurance, they would not have stayed afloat. "The biggest thought I had was, 'What's going to happen to my family if I'm not here?', because I was the main income earner." In the darkest days, Andrew wanted to give up treatment many times, but he said it was after he had his stoma removed that the real problems began. A stoma is a surgically created opening in the abdomen with a bag attached to collect stool. As his bowel recovered, Andrew found himself needing to go to the toilet between 20 and 50 times a day and he didn't leave the house for three months. Returning to work seemed impossible, but eventually he got on top of things, with the help of nutritionists from Bowel Cancer Australia. Even barbecues with friends took on a different flavour with Andrew needing to bring his own food and cook it in the oven instead of on charcoal to help keep his bowels in check. "It definitely sucks now I can't really drink much because it makes my stomach play up — I can't have a barbecue cooked on charcoal. "Going to a restaurant is hard because I can't eat garlic. I can't eat onions." These days, Andrew is trying to make the most of life and has scaled back at work to coach his daughters' rugby league teams. "I kind of used to be work first, now I'm a bit more family first." Andrew said a practical support for anyone going through bowel cancer would include a referral to a nutritionist who could offer advice to help manage bowel movements. "The nutritionist helped me probably the most out of anyone. I had to eat smaller meals. I went straight to eating boiled rice and a few veggies and really watching what fibre I ate." His message is to get checked early to avoid the worst side effects of serious treatment. "If you really think something is wrong, go get a second opinion."
